Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald Sells 1,598 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Kevin Joseph Fitzgerald sold 1,598 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the transaction, the executive vice president directly owned 23,512 shares in the company, valued at $7,703,706.80. This represents a 6.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kevin Joseph Fitzgerald also recently made the following trade(s):

• On Tuesday, March 3rd, Kevin Joseph Fitzgerald sold 1,652 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $319.73, for a total value of $528,193.96.
• On Tuesday, February 17th, Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $331.96, for a total value of $677,530.36.
• On Friday, February 13th, Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $310.08, for a total value of $607,446.72.
• On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $370.33, for a total value of $848,055.70.
• On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $8.65 during mid-day trading on Wednesday, reaching $327.30. The company had a trading volume of 931,139 shares, compared to its average volume of 1,481,848. The firm has a market cap of $43.41 billion, a price-to-earnings ratio of 191.40 and a beta of 0.36. The business’s 50-day simple moving average is $357.29 and its 200 day simple moving average is $417.03. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.65) earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $243,000. Geneos Wealth Management Inc. increased its position in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $43,000. Bessemer Group Inc. grew its position in Alnylam Pharmaceuticals by 77.8% in the 2nd quarter. Bessemer Group Inc. now owns 192 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 84 shares during the period. Finally, Hantz Financial Services Inc. bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $124,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALNY. Royal Bank Of Canada lowered their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Wall Street Zen lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Finally, Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.